17 September 2024
17 September 2024
Despite positive KEYNOTE-811 results, Merck & Co’s position in this setting is not devoid of threats from other competitors.
As Ipsen pivots away from Cabometyx in mCRPC, US rights holder Exelixis will press ahead with a submission to the FDA.
The Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.
As more drugs approach late-stage development for PAH, Cereno Scientific’s CEO expects more successful disease-modifying therapies.
The move ensures availability of the preventive treatment for babies ahead of the 2024/25 RSV season.
The therapy is currently in Phase I/Ib clinical development for patients with relapsed/refractory multiple myeloma.
The BTD was granted based on the interim results of the Phase III DREAMM-7 trial, which met its primary endpoint.
Kamau Therapeutics will gain non-exclusive research, clinical and commercial rights to utilise MaxCyte's Flow Electroporation technology and ExPERT platform.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
